Impact BioMedical to consolidate shares in 1-for-12.62 reverse stock split on Sept. 23
IBO•Share count and merger context
Outstanding shares are expected to fall to about 8,543,679 from about 107,821,231, subject to rounding.
The move supports a proposed merger with Zoar; Impact holders are expected to receive 1 Zoar share per 4 Impact shares post-split.
Reverse stock split effective Sept. 23
Impact BioMedical set a 1-for-12.62 reverse stock split, effective 12:01 a.m. ET on Sept. 23, 2026.
Shares will continue to trade on NYSE American under the ticker IBO, with a new CUSIP assigned.
